Related Experiment Video
Updated: Dec 25, 2025

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014
Marc Scherlinger1, Philippe Mertz2, Flora Sagez2
1Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Place Amélie Raba Léon, 33076 Bordeaux, France; CNRS-UMR 5164 ImmunoConcEpT, 146 rue Léo Saignat, 33076 Bordeaux, France; Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-Ouest (RESO), France.
Insights
Mortality rates for autoimmune diseases varied globally between 2001-2014. While some autoimmune systemic diseases (AISDs) saw declining deaths, others increased, highlighting global health inequities.
Area of Science:
- Epidemiology of autoimmune systemic diseases (AISDs).
- Global health and mortality trends.
- Rare disease research.
Background:
- Autoimmune systemic diseases (AISDs) encompass a group of chronic conditions with significant global health implications.
- Understanding temporal trends in mortality for AISDs is crucial for public health planning and resource allocation.
- Previous research has indicated geographical variations in AISD prevalence and outcomes.
Purpose of the Study:
- To analyze changes in mortality rates for six key AISDs between 2001 and 2014.
- To investigate these mortality trends at country, continent, and global levels.
- To identify disparities in mortality across different geographical regions.
Main Methods:
- Utilized World Health Organization (WHO) mortality database and ICD-10 codes for data retrieval.
- Calculated age-standardized mortality rates (ASMR) per million inhabitants with 95% confidence intervals (95%CI).
- Employed multivariate Poisson regression for association analysis and Jointpoint software for temporal trend analysis.
Main Results:
- In 2014, worldwide ASMR varied: SLE (2.68), SSc (1.46), IIM (0.47), SS (0.17), MCTD (0.11), and AAV (0.53) deaths/million.
- Significant worldwide ASMR decreases observed for SSc (-0.71%/year), IIM (-1.65%/year), and AAV (-1.01%/year) from 2001-2014.
- Worldwide ASMR for SS increased (+1.53%/year), while SLE showed an initial decrease followed by a slight increase.
Conclusions:
- Significant heterogeneity in AISD mortality rates exists across countries, underscoring global inequities.
- Identified major gaps in access to care, diagnosis, and management strategies for rare autoimmune diseases.
- Findings are critical for global physicians, patient associations, and policymakers to address health disparities.
Aim:
To describe changes in the 2001-2014 mortality of 6 autoimmune systemic diseases (AISDs), namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathies (IIM), Sjögren's Syndrome (SS), Mixed Connective Tissue Disease (MCTD) and ANCA-associated vasculitis (AAV) at the country-, continent-, and world-levels.
Methods:
Mortality data were retrieved from the World Health Organization (WHO) mortality database for each disease, based on ICD-10 codes. We computed age-standardized mortality rate (ASMR) as the estimated number of deaths per million inhabitants and its 95% confidence interval (95%CI). The association between gender, geographical areas and disease-specific mortality was analyzed using multivariate Poisson regression. The 2001-2014 temporal trends were analyzed using Jointpoint software.
Results:
In 2014, the worldwide ASMR for SLE was 2.68 (95%CI: 2.62-2.75) deaths/millions inhabitants, 1.46 (1.42-1.51) for SSc, 0.47 (0.44-0.49) for IIM, 0.17 (0.15-0.18) for SS, 0.11 (0.10-0.13) for MCTD and 0.53 (0.50-0.56) for AAV, with ASMRs generally lower in Europe than in North America, Latin America and Asia. Between 2001 and 2014, the worldwide ASMR decreased significantly for SSc (-0.71%/year), IIM (-1.65%/year) and AAV (-1.01%/year; p < .001 for all) and increased for SS (+1.53%/year, p = .01). The worldwide ASMR of SLE decreased significantly between 2001 and 2003 (-6.37%, p < .05) before increasing slightly between 2004 and 2014 (+0.58%, p < .01).
Conclusions:
We observed a strong heterogeneity of standardized mortality rates across all countries analyzed for 6 autoimmune diseases. Those results further highlight the impact of world-wide inequities and major gaps in access to care and strategies for diagnosis and management of rare diseases, a crucial finding for world-wide physicians, patient associations and policy makers.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Coronary Artery Disease I: Introduction

